5 Stocks Poised for Breakouts: RetailMeNot, Repros and More
at The Street - Fri Dec 19, 12:29PM CST
These are the stocks that often go on to make monster moves to the upside.
QEPM: 15.83 (-0.01), BDR: 2.36 (+0.06), CYBR: 41.60 (+0.59), SALE: 14.83 (+0.19), RPRX: 8.88 (+0.24)
Nominees for Absolute Worst Bio-Technology CEOs of 2014 Are ...
at The Street - Mon Dec 15, 10:49AM CST
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
NWBO: 5.58 (+0.04), DNDN: 0.13 (-0.02), RTRX: 12.92 (+0.19), CYTR: 2.58 (+0.03), RPRX: 8.88 (+0.24), GALE: 1.49 (-0.02), AEGR: 21.59 (-0.27)
Earnings Look Back: Repros Therapeutics Is Down 4.7% Since Reporting Quarterly Results 2 Weeks Ago (RPRX)
Comtex SmarTrend(R) - Mon Nov 24, 9:51AM CST
When Repros Therapeutics (NASDAQ:RPRX) reported earnings two weeks ago on November 10th, 2014, analysts, on average, expected the company to report a loss of $0.39 on sales of $1.0 thousand. The company actually reported a loss of $0.32 per share on sales of $2.0 thousand, beating EPS estimates by $0.07 and matching revenue estimates. Since the company's report, shares of Repros Therapeutics have fallen from $9.22 to $8.79, representing a loss of 4.7% in the past 14 days.
RPRX: 8.88 (+0.24)
Earnings Look Back: Repros Therapeutics Is Up 1.3% Since Reporting Quarterly Results 1 Week Ago (RPRX)
Comtex SmarTrend(R) - Mon Nov 17, 4:05PM CST
7 days ago, on November 10th, 2014, Repros Therapeutics (NASDAQ:RPRX) reported its earnings. Analysts, on average, expected a loss of $0.39 per share on sales of $1.0 thousand. The company actually reported a loss of $0.32 per share on sales of $2.0 thousand, beating EPS estimates by $0.07 and matching revenue estimates. Since the company's report, shares of Repros Therapeutics have risen from $9.22 to $9.34, representing a gain of 1.3% in the past 7 days.
RPRX: 8.88 (+0.24)
Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
CLUB: 5.90 (-0.07), HYGS: 13.33 (+0.06), KNDI: 12.90 (+0.99), MCEP: 6.07 (-0.12), HYG.TO: 15.50 (-0.16), RPRX: 8.88 (+0.24), SHLD: 32.56 (-0.37), PAA.TO: 10.51 (+0.27), PAAS: 9.05 (+0.25), REXX: 5.17 (-0.17), AKBA: 11.23 (-0.31), GCBC: 29.00 (-1.00), ASEI: 51.61 (+0.05), MTEX: 28.96 (unch), PLNR: 7.04 (-0.15)
Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:20PM CST
Shares of Repros Therapeutics (RPRX) shot up 56.9% following a successful meeting with the FDA regarding Androxal.
BIIB: 340.89 (+5.13), RPRX: 8.88 (+0.24), ABBV: 66.21 (+1.86), AMAG: 43.02 (+0.90)
Repros Therapeutics posts 3Q loss
Automated Insights - Mon Nov 10, 8:13AM CST
WOODLANDS, Texas (AP) _ Repros Therapeutics Inc. (RPRX) on Monday reported a loss of $7.4 million, or 32 cents per share, in its third quarter.
RPRX: 8.88 (+0.24)
Repros Therapeutics beats by $0.07
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:11AM CST
RPRX: 8.88 (+0.24)
Repros Therapeutics Inc.(R) Reports Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 10, 8:00AM CST
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced financial results for the third quarter ended September 30, 2014.
RPRX: 8.88 (+0.24)
Sears Soars Nearly +40% As REIT News Boosts Confidence
at The Street - Fri Nov 07, 2:42PM CST
Repros Therapeutics Inc (NASDAQ:RPRX), Sears Holdings Corp (NASDAQ:SHLD) and Allied Nevada Gold Corp. (NYSEMKT:ANV) are among the top-gaining billionaire stock picks of the day. On the losing end ar...
ANV: 0.88 (+0.02), AMSC: 0.82 (+0.01), RPRX: 8.88 (+0.24), SHLD: 32.56 (-0.37), STAY: 19.60 (-0.31)
Midday Gainers/Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 11:52AM CST
ROKA: 4.60 (-0.09), NES: 4.96 (-0.44), FNGN: 37.85 (+0.79), FIVN: 4.56 (+0.11), MSON: 11.76 (+0.14), SLXP: 114.92 (-1.18), SUMR: 3.10 (+0.06), RPRX: 8.88 (+0.24), QTWO: 20.09 (-0.21), EV: 41.98 (-0.25), SHLD: 32.56 (-0.37), STAY: 19.60 (-0.31), PSIX: 53.57 (-0.12), BORN: 1.38 (+0.02), URRE: 1.93 (+0.01), ECOM: 21.95 (+0.19), ICPT: 151.49 (+5.85), SAEX: 4.60 (+0.05), VPCO: 1.30 (-0.01), SZYM: 2.70 (+0.04)
Repros Therapeutics (RPRX) Stock Skyrockets After Meeting with FDA About Androxal
at The Street - Fri Nov 07, 10:07AM CST
Shares of Repros Therapeutics (RPRX) soared in morning trading Friday after the biopharmaceutical company held what it called a "constructive meeting" with the FDA regarding its testosterone-boosting drug Androxal.
RPRX: 8.88 (+0.24)
Repros jumps after FDA meeting on Androxal NDA
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 9:20AM CST
RPRX: 8.88 (+0.24)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:14AM CST
BEBE: 2.48 (-0.15), ANET: 65.00 (+0.30), TKMR: 13.97 (+0.14), ORBC: 6.71 (+0.17), MDRX: 12.87 (-0.13), RMTI: 8.41 (-0.07), CTIC: 2.36 (+0.05), SHLD: 32.56 (-0.37), UBNT: 31.30 (+0.14), RIG: 18.77 (-0.37), KGC: 2.70 (+0.11), APT: 2.55 (-0.03), ANF: 28.06 (-0.17), MITK: 3.47 (-0.06), ZNGA: 2.71 (-0.01), CNET: 1.28 (-0.11), KING: 16.27 (+0.10), NETE: 1.20 (unch), SLXP: 114.92 (-1.18), RPRX: 8.88 (+0.24), NADL: 1.68 (-0.08), PGNX: 6.99 (-0.03), AVNR: 16.91 (+0.01), FSLR: 43.67 (-0.39), DVA: 76.06 (+0.07), NDLS: 25.88 (+0.20), ICPT: 151.49 (+5.85), AGIO: 109.67 (+2.45), PLNR: 7.04 (-0.15)
Repros Holds Constructive Meeting With FDA Regarding Androxal(R) NDA Filing
GlobeNewswire - Thu Nov 06, 3:21PM CST
-- No New Clinical Studies Requested
RPRX: 8.88 (+0.24)
Will Repros (RPRX) Miss Estimates This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:12PM CST
Repros Therapeutics Inc. (RPRX) has an earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 97.84 (-0.29), PBH: 34.02 (+0.06), RPRX: 8.88 (+0.24), HSP: 62.60 (-0.07)
63.7% Return Seen to Date on SmarTrend Repros Therapeutics Call (RPRX)
Comtex SmarTrend(R) - Mon Nov 03, 10:56AM CST
SmarTrend identified a Downtrend for Repros Therapeutics (NASDAQ:RPRX) on September 4th, 2014 at $17.86. In approximately 2 months, Repros Therapeutics has returned 63.72% as of today's recent price of $6.48.
RPRX: 8.88 (+0.24)
Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings
PR Newswire - Mon Nov 03, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Repros Therapeutics Inc. (NASDAQ: RPRX), Nektar Therapeutics (NASDAQ: NKTR), Akorn Inc. (NASDAQ: AKRX), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 31, 2014, the NASDAQ Composite ended at 4,630.74, up 1.41%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 17,390.52, and the S&P 500 closed at 2,018.05, up 1.17%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.85, up 0.51%, with the index also advancing 10.60% in the previous three months. Register for your complimentary reports on these five stocks at:
ACRX: 6.61 (+0.06), PTX: 9.05 (+0.28), AKRX: 36.47 (+0.43), RPRX: 8.88 (+0.24), NKTR: 15.02 (+0.23)